Columbia SOM
The Tabas Laboratory
PublicationsLab MembersContact Usprotocolsbriefs

The Tabas laboratory studies the cellular biology of cardiometabolic disease, with an emphasis on the molecular-cellular mechanisms of advanced atherosclerosis and hepatic insulin resistance and NASH in obesity, and the links between these processes

The studies on advanced atherosclerosis have focused on integrated processes that combine to promote advanced plaque progression, with the current focus on defective clearance of the apoptotic cells (efferocytosis) and impaired inflammation resolution. In the efferocytosis field, we study (a) a macrophage receptor called MerTK; and (b) a process called high-burden efferocytosis, whereby a macrophage ingests and degrades multiple apoptotic cells over a short time period, requiring reprogramming of vesicular trafficking pathways and metabolism of molecules from degraded apoptotic cells. The inflammation resolution project investigates cellular mechanisms of the resolution process and its therapeutic potential, e.g., through the use of atherosclerosis-targeted nanoparticles packaged with resolution mediators. An exciting new area in the lab involves identifying specific mechanistic links between impaired resolution pathways and clonal hematopoiesis of indeterminate potential (CHIP), which is a major risk factor for atherosclerosis and coronary artery disease in humans over the age of 60.

The lab's studies on hepatic insulin resistance, which is an important driver of atherosclerosis, led to the discovery of a new calcium-stimulated pathway in hepatocytes that plays a key role in glucagon-mediated excessive glucose production, insulin resistance, fatty liver, dyslipidemia, impaired thrombolysis, and adipose tissue inflammation in the setting of obesity and type 2 diabetes. Ongoing studies are investigating: (a) the detailed molecular mechanisms involved in this new pathway; (b) how the pathway may promote atherosclerotic plaque progression by affecting plaque macrophages; and (c) strategies to translate our discoveries into new types of drugs to treat type 2 diabetes and prevent diabetes-driven atherosclerotic plaque progression.

Related to the lab's metabolism work, we study hepatocyte pathways in non-alcoholic steatohepatitis (NASH), with current investigations focused on (a) the role of a transcription factor called TAZ in both NASH fibrosis and NASH-associated hepatocellular carcinoma; (b) new mechanistic insight into known human genetic risk factors for NASH fibrosis, with current focus on MERTK and PNPLA3; and (c) new therapeutic strategies to prevent steatosis-to-NASH progression based on our findings.

The overall approach of the laboratory is to elucidate in-depth mechanisms using molecular-cell biological approaches; test causation in normal physiology and disease models using genetically engineered mice; probe relevance to humans through the study of normal and diseased human tissues and human genetics; and conceive and test novel and mechanism-based therapies in the cardiometabolic arena. In collaboration with the CUMC Cardiovascular and Metabolic Precision Medicine Program, led by Dr. Muredach Reilly, an important new, emerging direction in the lab is to apply our mechanistic insights related to advanced plaque progression and cardiometabolic disease to human genetics and studies with human iPSC-derived macrophages that can be genetically engineered using CRISPR/Cas9 to mimic or "correct" disease-causing human mutations.

The laboratory's philosophy is one of collaboration, not competition, and emphasis is placed on long-term, in-depth, and rigorous studies. Dr. Tabas places great emphasis on mentoring, particularly fostering independence, and career guidance. His trainees have had great success in career development grants from the NIH (K99/R00) and American Heart Association and subsequently with NIH R01 grants soon after leaving the lab for independent tenure-track Assistant Professorships at major university research organizations.

Postdoctoral Research Position:
The laboratory of Dr. Ira Tabas ( at Columbia University Medical Center is seeking a talented postdoctoral research scientist with expertise in molecular and cellular biology. The lab studies how inflammation, impaired resolution of inflammation, and perturbed metabolic signaling pathways, particularly in macrophages and hepatocytes, contribute to atherosclerosis and obesity/insulin resistance as part of the integrated process of cardiometabolic disease.

Although experience in the specific area of cardiometabolic disease is not required, priority will be given to candidates who have successfully completed in-depth mechanistic studies using both cells and genetically altered mouse models. In addition, in view of new directions currently in progress in the lab, priority will also be given to candidates with backgrounds in (a) bioinformatic genetic analyses, including applications to both whole tissue and single cell sequencing studies; and (b) studies into the functional implications of human gene variations, including the use of iPSC cells.

Candidates with the following qualifications will be considered: (1) a Ph.D. or M.D/Ph.D., with no more than 3 years post-graduation for PhD graduates; (2) first author high-quality publications published in first-rate journals; (3) experience in the research strategies and approaches outlined above; and (4) excellent communication skills, particularly ability to comprehend rapidly spoken English and to speak English fluently, both in 1:1 discussions and during seminar presentations.

Interested candidates who meet these qualifications should send cover letter and CV to Columbia University Medical Center is an Equal Opportunity/Affirmative Action Employer

Ira Tabas, MD, PhD

Richard J. Stock Professor and Vice-Chair of Research
Department of Medicine
Professor of Pathology & Cell Biology (in Physiology and Cellular Biophysics)
Columbia University Medical Center

Department of Medicine
Columbia University

630 West 168th Street
New York, NY 10032

Office: PH 8-East-105F
Laboratory: PH 9-405/406
Tel (office): 212-305-9430
Tel (lab): 212-305-5669
Fax: 212-305-4834

What's New?

Press Release

Change in Mitochondria is Critical for Clearing Dead Cells.
September 21, 2017


TABAS AND GLASS, 339 (6116): 166-172

January 11, 2013

Ira Tabas [of Columbia University’s Department of Medicine] reviews recent advances in anti-inflammatory therapies in treating and preventing chronic disease. “Inflammation, once it gets going, can lead to tissue destruction. So the very elements of inflammation that can destroy the invading organisms can also destroy host tissue. And when tissue gets damaged, it can lead to tissue disfunction, according to Dr. Tabas.

Copyright © 2018 Ira Tabas, MD, PhD. All Rights Reserved.